RIFLE: a Phase II trial of stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer.

Gastroenterol Rep (Oxf) · 2023 · PMC10568524 · PMID 37842200

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

The incidence rate was ∼29.51% in 2016, ranking among the top four, with an increasing trend year by year [ 1 ].

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.